Tvardi Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Tvardi Therapeutics's estimated annual revenue is currently $3.6M per year.
- Tvardi Therapeutics's estimated revenue per employee is $155,000
Employee Data
- Tvardi Therapeutics has 23 Employees.
- Tvardi Therapeutics grew their employee count by 28% last year.
Tvardi Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Co-founder Tvardi Therapeutics Inc. | Reveal Email/Phone |
2 | CEO | Reveal Email/Phone |
3 | SVP R&D | Reveal Email/Phone |
4 | VP, CMC | Reveal Email/Phone |
5 | VP, Development | Reveal Email/Phone |
6 | Chief Medical Officer | Reveal Email/Phone |
7 | Executive Director Development | Reveal Email/Phone |
8 | Sr. Clinical Project Manager | Reveal Email/Phone |
9 | Senior Manager R&D | Reveal Email/Phone |
10 | CMC Program Manager | Reveal Email/Phone |
Tvardi Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $1.7M | 11 | -8% | N/A | N/A |
#2 | $14.9M | 96 | -6% | N/A | N/A |
#3 | $15.2M | 98 | 3% | $1.8M | N/A |
#4 | $1.6M | 10 | 0% | N/A | N/A |
#5 | $3.4M | 22 | 0% | N/A | N/A |
#6 | $2.8M | 18 | 50% | N/A | N/A |
#7 | $7.4M | 48 | -2% | N/A | N/A |
#8 | $0.8M | 5 | 0% | N/A | N/A |
#9 | $1.6M | 10 | 0% | N/A | N/A |
#10 | $16.3M | 105 | 62% | N/A | N/A |
What Is Tvardi Therapeutics?
Tvardi Therapeutics is a clinical stage, private biotechnology company developing a new class of breakthrough medicines for diverse cancers, chronic inflammatory diseases and fibrotic diseases. Founded in 2017 and based in Houston, Texas, the company is led by experienced entrepreneurs, innovative scientists and dedicated physicians. Tvardi is focused on the development of inhibitors of STAT3, a key signaling molecule positioned at the intersection of many pathways controlling gene networks integral to the survival and immune sequestration of cancer cells as well as to the pathogenesis of many inflammatory and fibrotic conditions. Tvardi is conducting a first-in-human Phase Ia dose-escalating study to determine safety and dosing for follow-on studies for its lead compound, TTI-101. Collectively, the societal and economic impact of STAT3-dependent disease is significant. Tvardi is highly motivated to develop safe and effective small molecule inhibitors of STAT3 for use across numerous diseases.
keywords:N/A
N/A
Total Funding
23
Number of Employees
$3.6M
Revenue (est)
28%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Tvardi Therapeutics News
Tvardi Therapeutics to Participate in Morgan Stanley Private Company Biotech Corporate Access Day. April 28, 2022 04:00 PM Eastern Daylight Time.
Tvardi Therapeutics, a clinical-stage biopharmaceutical company, has announced receipt of orphan drug designation (ODD) from the US Food and...
Tvardi Therapeutics' TTI-101 Receives Orphan Drug Designation for Hepatocellular Carcinoma. Published: Apr 21, 2022. April 21, 2022 12:00 UTC.
Tvardi Therapeutics, Inc., a Houston, Texas-based clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, closed a $74m Series B financing. The round was led by new investors Slate Path Capital, Palkon Capital, ArrowMark Partners, and 683 Capital, with participa ...
Tvardi Therapeutics Inc., a Houston, TX-based clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, raised over $5m in non-dilutive grants. The three National Cancer Institute (NCI) funding awards are two Specialized Programs of Research Excellence (SPORE) gra ...
Other Companies in Houston
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $2.3M | 23 | N/A | N/A |
#2 | $2.3M | 23 | N/A | N/A |
#3 | $5.3M | 23 | 0% | N/A |
#4 | $1.5M | 23 | -45% | $4.4M |
#5 | $2.7M | 23 | -4% | N/A |